MRGN Advisors - Geneva

  • Home
  • About
  • Partners
  • Capabilities
  • News
  • Contact
  • Home
  • About
  • Partners
  • Capabilities
  • News
  • Contact

Zambon completes transformational acquisition of Breath Therapeutics

29/7/2019

 
Zambon, a privately held long-established Italian multinational company, extends its presence in severe respiratory diseases through the acquisition of Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), a rare fatal respiratory disease currently in phase III. 
  • Acquisition reinforces Zambon’s strategy to grow through further globalization and continued investment in Specialty Care. 
  • Highly synergistic combination of Breath Therapeutics’ late-stage respiratory drug together with Zambon’s established expertise and commercialization infrastructure. 
  • Zambon’s severe respiratory disease business now includes two leading projects in phase III, both with broad geographic outreach, including USA. 
  • Price acquisition is €140 million with a total maximum up to €500 million subject to regulatory and sales milestones.

Read More

    MRGN Advisors

    MRGN Advisors 
    Rue du Mont-Blanc 4    
    Case postale 2067    
    CH - 1211 Genèva 1 
    Switzerland

    Archives

    October 2020
    September 2020
    November 2019
    July 2019
    February 2019
    February 2018
    November 2017
    February 2017
    January 2017
    January 2016
    December 2015
    November 2015
    June 2015
    January 2015
    June 2014
    May 2014
    April 2014
    March 2014
    January 2014
    November 2013
    October 2013
    September 2013
    June 2013
    January 2012

    Categories

    All

    RSS Feed

MRGN Advisors
The company is a healthcare consultancy established in 2015
Galeries Benjamin-Constant 1 | c/o PLUS Fiduciaire | CH - 1003 Lausanne  |  ​Switzerland  |  info@mrgnadvisors.com
Création de site Internet